Entities/Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

Company
10 indicators

Net income

-1.58M

Not enough historical data

Diluted earnings per share (diluted EPS)

-0.31

Not enough historical data

Net cash flows from operating activities

-1.18M

Not enough historical data

Operating income

-1.62M

Not enough historical data

Operating expenses (excl. COGS)

1.62M

Not enough historical data

Research & development expense

281.81K

Not enough historical data

Financial

IndicatorLatest ValueYear

Total assets

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

7.69M2025

Total liabilities

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

2.42M2025

Total stockholders' equity

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

5.27M2025

Net cash provided by financing activities

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

2.83M2025